Novartis AG (NVS) Earnings History
Growth Compounder28 years of earnings data (1998–2025) · Consistent double-digit EPS growth over 5 years
Loading earnings history...
Novartis AG (NVS) Earnings Overview
As of June 23, 2026, Novartis AG (NVS) reported trailing twelve-month net income of $13.53B, reflecting +22.5% year-over-year growth. The company earned $7.06 per diluted share over the past four quarters, with a net profit margin of 25.6%.
Looking at the long-term picture, NVS's 5-year EPS compound annual growth rate (CAGR) stands at +15.4%, indicating exceptional earnings growth. The company achieved its highest annual net income of $24.02B in fiscal 2021.
Novartis AG maintains industry-leading profitability with a gross margin of 75.0%, operating margin of 31.2%, and net margin of 25.6%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PFE ($7.49B net income, 12.4% margin), AZN ($10.39B net income, 17.5% margin), NVO ($121.96B net income, 33.1% margin), NVS has outperformed on profitability metrics. Compare NVS vs PFE →
NVS Earnings vs Peers
Earnings metrics vs comparable public companies
NVS Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.06B | +17.7% | $17.07B | $7.19 | 25.6% | 31.2% |
| 2024 | $11.94B | -19.6% | $14.54B | $5.87 | 23.1% | 28.1% |
| 2023 | $14.85B | +113.5% | $9.77B | $7.10 | 31.8% | 20.9% |
| 2022 | $6.96B | -71.0% | $7.95B | $3.17 | 16.0% | 18.3% |
| 2021 | $24.02B | +197.6% | $10.06B | $10.63 | 54.6% | 22.9% |
| 2020 | $8.07B | -31.2% | $10.15B | $3.52 | 16.2% | 20.3% |
| 2019 | $11.73B | -7.0% | $9.09B | $3.08 | 24.1% | 18.7% |
| 2018 | $12.61B | +63.7% | $8.40B | $5.38 | 27.4% | 18.2% |
| 2017 | $7.70B | +14.8% | $8.70B | $3.25 | 17.7% | 20.0% |
| 2016 | $6.71B | -62.3% | $8.27B | $2.80 | 13.6% | 16.7% |
| 2015 | $17.78B | +74.2% | $8.98B | $7.29 | 35.3% | 17.8% |
| 2014 | $10.21B | +11.3% | $11.09B | $4.13 | 19.0% | 20.7% |
| 2013 | $9.18B | -1.0% | $10.98B | $3.70 | 17.4% | 20.8% |
| 2012 | $9.27B | +3.7% | $11.51B | $3.89 | 17.8% | 22.1% |
| 2011 | $8.94B | -8.7% | $10.78B | $3.70 | 15.1% | 18.2% |
| 2010 | $9.79B | +16.6% | $11.53B | $4.26 | 19.0% | 22.4% |
| 2009 | $8.40B | +2.5% | $9.98B | $3.69 | 18.6% | 22.1% |
| 2008 | $8.20B | -31.4% | $8.96B | $3.59 | 19.2% | 21.1% |
| 2007 | $11.95B | +66.5% | $6.78B | $5.13 | 30.7% | 17.4% |
| 2006 | $7.17B | +17.0% | $7.64B | $3.04 | 20.4% | 21.8% |
| 2005 | $6.13B | +14.3% | $6.51B | $2.62 | 20.6% | 21.9% |
| 2004 | $5.37B | +13.1% | $6.12B | $2.27 | 19.7% | 22.4% |
| 2003 | $4.74B | +0.4% | $5.63B | $1.97 | 19.0% | 22.6% |
| 2002 | $4.72B | +23.2% | $5.09B | $1.84 | 22.6% | 24.4% |
| 2001 | $3.84B | -14.1% | $4.33B | $1.49 | 20.4% | 23.1% |
| 2000 | $4.47B | +6.8% | $4.88B | $1.70 | 20.1% | 22.0% |
| 1999 | $4.18B | -4.3% | $4.61B | $0.62 | 20.5% | 22.6% |
| 1998 | $4.37B | - | $5.03B | $0.33 | 19.0% | 21.8% |
Download Data
Export NVS earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into NVS consensus models and risk factors.
Should I Buy NVS?
Wall Street verdict, signals, and target summaries.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVS — Frequently Asked Questions
Quick answers to the most common questions about buying NVS stock.
What is NVS earnings per share (EPS)?
NVS trailing twelve-month (TTM) diluted EPS is $7.06, reflecting +22.5% year-over-year growth. The 5-year EPS CAGR is +15.4%. Complete EPS history from 1998 to 2025 is available in the table on this page.
What is Novartis AG's net income?
Novartis AG (NVS) trailing twelve-month net income is $13.5B as of 2025. Earnings grew +22.5% year-over-year. Novartis AG has been profitable for 28 consecutive years.
Is NVS profitable?
Yes, NVS is profitable with a TTM net income of $13.5B and a net profit margin of +25.6%. Novartis AG has generated profits for 28 consecutive years.
What is NVS's earnings growth rate?
NVS compound annual EPS growth rates (CAGR): 1-Year: +22.5%, 3-Year: +31.4%, 5-Year: +15.4%, 10-Year: -0.1%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1998 to 2025.
What are NVS's profit margins?
Novartis AG net profit margin is +25.6%, operating margin is +31.2%, and gross margin is +75.0%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +31.0%.
Is NVS growing earnings?
Yes, NVS earnings are accelerating — EPS growth of +22.5% exceeds the 5-year CAGR of +15.4%. TTM net income reached $13.5B. Earnings momentum is strengthening.
What was NVS's best earnings year?
Novartis AG's highest annual net income on record is $24.0B, achieved in fiscal year 2021. Earnings history on this page spans 1998 to 2025 and includes all annual and quarterly figures.
What were NVS's earnings last quarter?
NVS's most recent reported quarter was Q1 2026. Net income was $3.2B with diluted EPS of $1.65. For a full breakdown of all quarters, see the quarterly earnings table on this page.